Genetic testing for hereditary mutations in the RET gene
Medical Services Advisory Committee
Record ID 32015000431
English
Authors' recommendations:
After considering the strength of the available evidence in relation to the safety, clinical effectiveness and cost-effectiveness of diagnostic genetic testing for hereditary mutations in the RET gene, MSAC supports public funding via a new MBS item, with an item descriptor of:
Category 6 – Pathology services
Detection of germline mutations in the RET gene in patients with a suspected clinical diagnosis of multiple endocrine neoplasia type 2 (MEN2).
1 test. Adequate for lifetime test.
Fee: $400
Explanatory Note: Prior to ordering these tests the ordering practitioner must ensure that the patient (or an appropriate proxy) has given informed consent. Testing can only be performed after genetic counselling. Appropriate genetic counselling should be provided to the patient either by the specialist treating practitioner, a genetic counselling service or a clinical geneticist on referral. Further counselling may be necessary upon receipt of the test results.
After considering the strength of the available evidence in relation to the safety, clinical effectiveness and cost-effectiveness of predictive genetic testing for hereditary mutations in the RET gene, MSAC supports public funding via a new MBS item, with an item descriptor of:
Category 6 – Pathology services
Detection of a known mutation in the RET gene in an asymptomatic relative of a patient with a documented pathogenic germline RET mutation.
1 test. Adequate for lifetime test.
Fee: $200
Explanatory Note: Prior to ordering these tests the ordering practitioner must ensure that the patient (or an appropriate proxy) has given informed consent. Testing can only be performed after genetic counselling provided by a genetic counselling service or a clinical geneticist on referral. Further counselling may be necessary upon receipt of the test results.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1152-public
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Humans
- Genetic Testing
- Proto-Oncogene Proteins c-ret
Contact
Organisation Name:
Medical Services Advisory Committee
Contact Address:
MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name:
msac.secretariat@health.gov.au
Contact Email:
msac.secretariat@health.gov.au
Copyright:
Medical Services Advisory Committee (MSAC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.